Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23.
- Author:
Kyubo KIM
1
;
Hae Jin PARK
;
Kyung Hwan SHIN
;
Jin Ho KIM
;
Doo Ho CHOI
;
Won PARK
;
Seung Do AHN
;
Su Ssan KIM
;
Dae Yong KIM
;
Tae Hyun KIM
;
Jin Hee KIM
;
Jiyoung KIM
Author Information
- Publication Type:Multicenter Study ; Original Article
- Keywords: Triple negative breast neoplasms; Breast conservation therapy; Mastectomy
- MeSH: Breast Neoplasms; Breast*; Chemotherapy, Adjuvant; Follow-Up Studies; Humans; Lymph Nodes; Mastectomy*; Mastectomy, Segmental; Radiotherapy; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms*
- From:Cancer Research and Treatment 2018;50(4):1316-1323
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The aim of this study is to compare the treatment outcomes of breast conserving surgery (BCS) plus radiotherapy (RT) versus mastectomy for patients with pT1-2N1 triple-negative breast cancer (TNBC). MATERIALS AND METHODS: Using two multicenter retrospective studies on breast cancer, a pooled analysis was performed among 320 patients with pT1-2N1 TNBC. All patients who underwent BCS (n=212) receivedwhole breast RTwith orwithoutregional nodal RT,while nonewho underwent mastectomy (n=108)received it. All patients received taxane-based adjuvant chemotherapy. The median follow-up periods were 65 months in the BCS+RT group, and 74 months in the mastectomy group. RESULTS: The median age of all patients was 48 years (range, 24 to 70 years). Mastectomy group had more patients with multiple tumors (p < 0.001), no lymphovascular invasion (p=0.001), higher number of involved lymph node (p=0.028), and higher nodal ratio ≥ 0.2 (p=0.037). Other characteristics were not significantly different between the two groups. The 5-year locoregionalrecurrence-free, disease-free, and overall survivalrates of BCS+RT group versus mastectomy group were 94.6% versus 87.7%, 89.5% versus 80.4%, and 95.0% versus 87.8%, respectively, and the differences were statistically significant after adjusting for covariates (p=0.010, p=0.006, and p=0.005, respectively). CONCLUSION: In pT1-2N1 TNBC, breast conservation therapy achieved better locoregional recurrencefree, disease-free, and overall survival rates compared with mastectomy.
